BLFS (BioLife Solutions) Change In Working Capital : $-0.90 Mil (TTM As of Mar. 2025)

View and export this data going back to 1989. Start your Free Trial

What is BioLife Solutions Change In Working Capital?

BioLife Solutions's change in working capital for the quarter that ended in Mar. 2025 was $-3.76 Mil.

BioLife Solutions's change in working capital for the fiscal year that ended in Dec. 2024 was $0.23 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

BioLife Solutions Change In Working Capital Historical Data

The historical data trend for BioLife Solutions's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Change In Working Capital Chart

BioLife Solutions Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Working Capital

Get a 7-Day Free Trial

-1.10

-2.26

-14.91

1.47

0.23

BioLife Solutions Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Working Capital	Get a 7-Day Free Trial															-2.64	3.23	-1.49	1.12	-3.76

BioLife Solutions Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.90 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

BioLife Solutions Change In Working Capital Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLife Solutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

BJX1:Germany BJX1:Germany

Address

3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021

Website

https://www.biolifesolutions.com

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

Executives

Sarah Aebersold	officer: VP, Global Human Resources	BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman	officer: Chief Financial Officer	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Aby J. Mathew	officer: Chief Tech. Officer & Sr. VP	3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard	officer: Vice President, Marketing	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster	officer: Vice President of Operations	C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Amy Duross	director	8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Greef Roderick De	director
Garrie Richardson	officer: Chief Revenue Officer	3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Geraint Phillips	officer: SVP, Global Operations	3303 MONTE VILLA, #310, BOTHELL WA 98021
Michael Rice	director, officer: President & CEO	C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p.	10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Marcus Schulz	officer: Vice President, Global Sales	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick	director	16719 NE 139TH PLACE, WOODINVILLE WA 98072
Timothy L. Moore	director	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami	director	SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023